Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT02549261
- Locations
- 🇨🇳
Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)
- Conditions
- Extranodal NK-T-Cell Lymphoma
- Interventions
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT02544425
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Recurrent T Lymphoblastic Leukemia/LymphomaB Lymphoblastic LymphomaRecurrent B Lymphoblastic LymphomaRefractory T Lymphoblastic LymphomaT Lymphoblastic LymphomaB Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRefractory B Lymphoblastic LymphomaT Acute Lymphoblastic Leukemia
- Interventions
- Drug: AsparaginaseDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideDrug: EtoposideDrug: Imatinib MesylateOther: Laboratory Biomarker AnalysisDrug: PrednisoneBiological: RituximabDrug: Vincristine Sulfate
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- University of Washington
- Registration Number
- NCT02538926
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
- Conditions
- Acute,Leukemia, Lymphoid
- Interventions
- Drug: DasatinibDrug: prednisoneDrug: cyclophosphamideDrug: daunorubicinDrug: vincristineDrug: cytarabineDrug: mercaptopurineDrug: methotrexateDrug: dexamethasoneDrug: mitoxantroneDrug: etoposideProcedure: allogeneic hematopoietic stem cell transplantationProcedure: autologous hematopoietic stem cell transplantation
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Target Recruit Count
- 30
- Registration Number
- NCT02523976
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
- Conditions
- Acute Myeloid LeukemiaDown SyndromeMyelodysplastic SyndromeMyeloid Leukemia Associated With Down SyndromeMyeloproliferative Neoplasm
- Interventions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 280
- Registration Number
- NCT02521493
- Locations
- 🇨🇦
CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL), Quebec, Canada
🇳🇿Starship Children's Hospital, Grafton, Auckland, New Zealand
🇳🇿Christchurch Hospital, Christchurch, New Zealand
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
- Conditions
- Leukemia, B-CellLymphoma, Non-Hodgkin'sAcute Lymphoblastic LeukemiaLeukemia, T-Cell
- Interventions
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT02518750
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
- Conditions
- Refractory Solid TumorsRelapsed LeukemiaRelapsed Solid TumorsRefractory Leukemia
- Interventions
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 4
- Registration Number
- NCT02512926
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Penn State Hershey Children's Hospital, Hershey, Pennsylvania, United States
🇺🇸Stanford University School of Medicine and Stanford Cancer Institute, Palo Alto, California, United States
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
- Conditions
- Recurrent Plasma Cell MyelomaPlasma Cell Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: CarmustineDrug: CytarabineDrug: EtoposideDrug: Ixazomib CitrateDrug: MelphalanDrug: MethotrexateProcedure: Peripheral Blood Stem Cell TransplantationOther: Quality-of-Life AssessmentDrug: Tacrolimus
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 11
- Registration Number
- NCT02504359
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
- Conditions
- MedulloblastomaDiffuse Intrinsic Pontine GliomaGlioblastoma MultiformeMalignant Brain TumorEpendymomaGliosarcomaGliomaPrimary CNS Tumor
- Interventions
- Drug: IndoximodDrug: TemozolomideDrug: CyclophosphamideRadiation: Conformal RadiationDrug: Etoposide
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 81
- Registration Number
- NCT02502708
- Locations
- 🇺🇸
Children's Heathcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Augusta University, Augusta, Georgia, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT02499770
- Locations
- 🇺🇸
Roswell Park, Buffalo, New York, United States
🇫🇷CHU de Rennes Hopital Pontchaillou, Rennes, France
🇺🇸Florida Cancer Specialists - South, Fort Myers, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.